Newsletters and more news updates

The latest winter newsletter is downloadable via this link (click link or right click and save as…).

David Casley, Prospect Publicity 07860 369064; Email  prospect.bristol@gmail.com

MORE NEWS

‘Nanoparticles kill cancer’

Scientists have created a “Trojan horse” that sneaks nanoparticles into cancer cells and causes them to self-destruct. The research is still in its early days, but the new method has already proved to be effective at killing cancer cells in a petri dish and reducing tumour growth in mice. See more

Killer virus attacks cancer

A genetically modified virus that kills cancer cells and destroys their hiding places has been developed by British scientists. The dual-action virus targets both cancer cells and healthy cells which have been tricked into protecting the cancer from the immune system. The Oxford University study is the first time cancer-associated fibroblasts or CAFs within solid tumours have been specifically targeted in this way (Nov ’19). See more here. And a simple new blood test has been found to detect aggressive prostate cancer, according to research by Queen Mary University of London. With the PSA test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment. The results need to be validated in other independent research centres before the new test is available, which could take 3-5 more years (Oct ’19). See more here. And UK researchers have developed a urine test to diagnose aggressive PCa and predict whether patients will need treatment up to five years earlier than standard clinical methods (Jun ’19). See more here

Drugs to attack resistant cancer

The world’s first drugs designed to stop cancer cells becoming resistant to treatment could be available within the next decade, scientists have said (May ’19). More here

A Bristol first – and sparing nerves

A Bristol man is the first NHS patient to have a device implanted which can reduce the side effects of radiotherapy by 70% (see more here). And a trial ito spare the nerves around the prostate during surgery is being held at Southmead Hospital. If successful, it will reduce the risk of erectile disfunction and will be available throughout England.

MRI scans to replace PSA?

Hundreds of UK men are trying out a non-invasive MRI scan for PCa to see if it should eventually be offered routinely on the NHS. The scan takes images to check for any abnormal growths. It will take a few years to know if MRI will be better than PSA tests and biopsies at spotting cancers (Jun ’19). In this article, a professor explains why finding a suitable screening method is vital but has proved difficult. And Prostate Cancer UK said the news made headlines but journalists “can be overly enthusiastic about new research” and put the record straight here. And an academic article on this is to be found here

Help with treatment – but beware

AN NHS tool is now available – intended for men with non-metastatic PCa who are deciding between conservative and radical management regimes. It is intended only for men with non-metastatic prostate cancer who are deciding between these regimes. It’s recommend that patients use this tool in consultation with their doctor (Apr ’19). See here. You may have read about this tool in newspapers, but not all the news was 100% accurate – check this NHS Behind The Headlines Page for the facts. And four new technologies that will tame the immune system are getting us closer to a future where cancer becomes curable. See more here

New guidance on active surveillance

New best-practice guidelines for doctors offering active surveillance have been published, as NICE recognise the procedure as being on a par with surgery and radiotherapy for men with low-risk localised PCa (May ’19). More here. And Prostate Cancer UK run a monthly group chat from men on active surveillance who want to share experiences and ask questions about the treatment. The group chat is on the second Tuesday of the month (7-8pm). Join the chat here.

At-home urine test created

A PCa test which can be carried out at home has been developed by university experts. Medics hope patients can receive an earlier and more accurate diagnosis by providing a urine sample. The test has been developed further so urine samples can be collected at home (Nov ’19). See more here. And scientists have created another urine test for PCa after trials on 155 men in Bristol (2016). See here

Anti-fatigue app approved

Untire has become the first Cancer-Related Fatigue (CRF) app to be approved by the NHS, and is now available to download for free via the NHS apps library. It aims to tackle CRF, one of the most common side effects of cancer and its treatment (Aug ’19). See more at

New hope for men whose cancer has spread

US clinical trials are likely to lead to approval of a new class of life-extending treatment options for men with metastatic hormone-sensitive PCa. This refers to men whose cancer has spread outside of the prostate and who are responsive to testosterone-lowering agents (July ’19). See more here

Broadcasters thanked

NHS head Simon Stevens thanked broadcasters Bill Turnbull and Stephen Fry for urging men to seek help (Oct ’18). See here.

Defeating therapy resistance

A new US study sheds light on a signalling circuit in cells that drives therapy resistance in PCa. Targeting the components of this circuit suppresses advanced cancer development. See here.

Laser treatment success

Surgeons described a new treatment for early stage PCa as “truly transformative”. The approach, tested in Europe, uses lasers and a drug made from deep-sea bacteria to kill tumours, without severe side effects. See here.

World first hailed

Scientists in Belfast claim a major breakthrough in PCa treatment. It is hoped the new discovery could help stop the spread of the disease and prevent relapses. Researchers have found that combining hormone therapy with a new drug, OCT1002, can improve treatment effectiveness. See here.

Drug targets tumours

A radioactive drug, which behaves like the substance used to kill Russian ex-spy Alexander Litvinenko, could be used to treat PCa patients. It targets tumours that have spread to the bones and has been approved by NICE. See here

Early detection claimed

Scientists at Israel’s Weizmann Institute might have found a PCa cure, at least if it’s caught early. See here.

New diagnosis tool; Zytiga affordable

A new risk assessment tool for GPs is set to revolutionise PCa diagnosis. See here. And NICE has agreed that abiraterone (Zytiga) is affordable after a lower price was agreed with the makers. See here.

More accurate predictions?

Patients might be offered a more accurate prediction of their PCa risk with a novel method developed by Cambridge University researchers. See here

Biopsies may be ‘out’

Urologists are committed to rolling out diagnostic use of the new MRI scans once their benefits are officially confirmed. The scans make it possible to rule out the need for a biopsy in many men who don’t have a clinically significant PCa. See here. Latest on this here. And US researchers have identified a marker of aggressive PCa. See here

Back to top